Clinical and laboratory features
| . | All patients, n = 131 . | LDOC1 positive, n = 46 . | LDOC1 negative, n = 85 . | P* . |
|---|---|---|---|---|
| Median age, y (range) | 59 (27-82) | 60 (27-82) | 59 (27-81) | .6796 |
| Sex | .7066 | |||
| Male, n (%) | 81 (62%) | 27 (59%) | 54 (64%) | |
| Female, n (%) | 50 (38%) | 19 (41%) | 31 (36%) | |
| Rai stage | (n = 131) | (n = 46) | (n = 85) | .826 |
| 0-2, n (%) | 102 (78%) | 35 (76%) | 67 (79%) | |
| 3-4, n (%) | 29 (22%) | 11 (24%) | 18 (21%) | |
| WBC count | (n = 131) | (n = 46) | (n = 85) | .0621 |
| ≤ 150 × 109/L, n (%) | 118 (90%) | 38 (83%) | 80 (94%) | |
| > 150 × 109/L, n (%) | 13 (10%) | 8 (17%) | 5 (6%) | |
| Serum β2 microglobulin† | (n = 130) | (n = 46) | (n = 84) | .1384 |
| < 4, n (%) | 98 (75%) | 31 (67%) | 67 (80%) | |
| ≥ 4, n (%) | 32 (25%) | 15 (33%) | 17 (20%) | |
| IGHV somatic mutation status† | (n = 130) | (n = 45) | (n = 85) | 2.20 × 10−16 |
| Mutated, n (%) | 67 (52%) | 2 (4%) | 65 (76%) | |
| Unmutated, n (%) | 63 (48%) | 43 (96%) | 20 (24%) | |
| ZAP70 protein status† | (n = 113) | (n = 39) | (n = 74) | 1.06 × 10−6 |
| Positive, n (%) | 51 (45%) | 30 (77%) | 21 (28%) | |
| Negative, n (%) | 62 (55%) | 9 (23%) | 53 (72%) | |
| Cytogenetic changes† | (n = 100) | (n = 39) | (n = 61) | .0005834 |
| None, n (%) | 27 (27%) | 14 (36%) | 14 (23%) | |
| Isolated del(13q), n (%) | 36 (36%) | 5 (13%) | 30 (49%) | |
| del(6q), del(11q), del(17p), +12, or del(13q) with other abnormalities, n (%) | 37 (37%) | 20 (51%) | 17 (28%) |
| . | All patients, n = 131 . | LDOC1 positive, n = 46 . | LDOC1 negative, n = 85 . | P* . |
|---|---|---|---|---|
| Median age, y (range) | 59 (27-82) | 60 (27-82) | 59 (27-81) | .6796 |
| Sex | .7066 | |||
| Male, n (%) | 81 (62%) | 27 (59%) | 54 (64%) | |
| Female, n (%) | 50 (38%) | 19 (41%) | 31 (36%) | |
| Rai stage | (n = 131) | (n = 46) | (n = 85) | .826 |
| 0-2, n (%) | 102 (78%) | 35 (76%) | 67 (79%) | |
| 3-4, n (%) | 29 (22%) | 11 (24%) | 18 (21%) | |
| WBC count | (n = 131) | (n = 46) | (n = 85) | .0621 |
| ≤ 150 × 109/L, n (%) | 118 (90%) | 38 (83%) | 80 (94%) | |
| > 150 × 109/L, n (%) | 13 (10%) | 8 (17%) | 5 (6%) | |
| Serum β2 microglobulin† | (n = 130) | (n = 46) | (n = 84) | .1384 |
| < 4, n (%) | 98 (75%) | 31 (67%) | 67 (80%) | |
| ≥ 4, n (%) | 32 (25%) | 15 (33%) | 17 (20%) | |
| IGHV somatic mutation status† | (n = 130) | (n = 45) | (n = 85) | 2.20 × 10−16 |
| Mutated, n (%) | 67 (52%) | 2 (4%) | 65 (76%) | |
| Unmutated, n (%) | 63 (48%) | 43 (96%) | 20 (24%) | |
| ZAP70 protein status† | (n = 113) | (n = 39) | (n = 74) | 1.06 × 10−6 |
| Positive, n (%) | 51 (45%) | 30 (77%) | 21 (28%) | |
| Negative, n (%) | 62 (55%) | 9 (23%) | 53 (72%) | |
| Cytogenetic changes† | (n = 100) | (n = 39) | (n = 61) | .0005834 |
| None, n (%) | 27 (27%) | 14 (36%) | 14 (23%) | |
| Isolated del(13q), n (%) | 36 (36%) | 5 (13%) | 30 (49%) | |
| del(6q), del(11q), del(17p), +12, or del(13q) with other abnormalities, n (%) | 37 (37%) | 20 (51%) | 17 (28%) |
Age, Rai stage, WBC count, and serum β2 microglobulin values are reported for the time the sample was obtained for LDOC1 mRNA expression; IGHV somatic mutation status, ZAP70 protein status, and cytogenetic changes were determined on samples obtained before treatment.
All P values were calculated using the 2-sided Fisher exact test except for age in years, which was calculated using the 2-sided t test.
For serum β2 microglobulin and IGHV somatic mutation status, 1 value was unavailable; for ZAP70 protein, 18 values were unavailable; and for genomic abnormalities, 31 values were unavailable.